Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Rel-ating myeloid cells to cancer therapy

Nature Cancer volume 1, pages 480–481 (2020)Cite this article

Subjects

Immune-checkpoint blockade holds great promise in cancer therapy; however, T cell–specific checkpoint inhibitors are not effective for all patients with cancer. The transcription factor c-Rel is now shown to regulate pro-inflammatory polarization of myeloid cells and modulate anti-tumor immune responses.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: c-Rel regulates myeloid cell suppression of anti-tumor immune responses.

References

  1. National Cancer Institute. National Cancer Act of 1971 (National Cancer Institute, 1971).

  2. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Cancer Treat. Rev. 86, 102019 (2020).

    Article  CAS  Google Scholar 

  3. Sharma, P. & Allison, J. P. Science 348, 56–61 (2015).

    Article  CAS  Google Scholar 

  4. Blank, C. U. et al. Nat. Rev. Immunol. 19, 665–674 (2019).

    Article  CAS  Google Scholar 

  5. Ribas, A. & Wolchok, J. D. Science 359, 1350–1355 (2018).

    Article  CAS  Google Scholar 

  6. Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Am. Soc. Clin. Oncol. Educ. Book 39, 147–164 (2019).

    Article  Google Scholar 

  7. Li, T. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-0061-3 (2020).

  8. Pathria, P., Louis, T. L. & Varner, J. A. Trends Immunol. 40, 310–327 (2019).

    Article  CAS  Google Scholar 

  9. Veglia, F., Perego, M. & Gabrilovich, D. Nat. Immunol. 19, 108–119 (2018).

    Article  CAS  Google Scholar 

  10. Sen, R. & Baltimore, D. Cell 46, 705–716 (1986).

    Article  CAS  Google Scholar 

  11. Gilmore, T. D. Oncogene 25, 6680–6684 (2006).

    Article  CAS  Google Scholar 

  12. Harling-McNabb, L. et al. Int. Immunol. 11, 1431–1439 (1999).

    Article  CAS  Google Scholar 

  13. Kaneda, M. M. et al. Nature 539, 437–442 (2016).

    Article  CAS  Google Scholar 

  14. Guerriero, J. L. et al. Nature 543, 428–432 (2017).

    Article  CAS  Google Scholar 

  15. Smale, S. T. Immunol. Rev. 246, 193–204 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA

    Hideyuki Takahashi & Judy Varner

  2. Department of Otolaryngology-Head and Neck Surgery, Gunma Univ. Grad. School of Medicine, Gunma, Japan

    Hideyuki Takahashi

  3. Department of Pathology, University of California, San Diego, La Jolla, CA, USA

    Judy Varner

Authors
  1. Hideyuki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judy Varner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hideyuki Takahashi or Judy Varner.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takahashi, H., Varner, J. Rel-ating myeloid cells to cancer therapy. Nat Cancer 1, 480–481 (2020). https://doi.org/10.1038/s43018-020-0069-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-020-0069-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer